jurnal tahun age GMFCs N N exp N kontrol

amanat 2021 4-14th level 2-5 72 36 36

cherynkh 2014 12bln-8th level 4-5 21 21 21 pre post

mean age
4.9th

englander 2015 me 2.4th 17

fu 2019 level 4-5 57 grup A ( one

course ):30; B
(2 course):27

gu 2020 39 20

huang 2018 3 to12 years, 54 27

liem 2018 level 3-5 20 10

liu 2017 6-150mo 102 BM MSCs : 33; 35

BM MNCs : 34

luan 2012 94 49 45
nguyen 2017 4y level 3-5 40 40 40(pre post)

sun 2017 level 1-4 63 32 31

(median age 2.1

years)
thanh 2019 2-15y level 2-4 25 25 25 (prepost)
(median :5.4y)

wang 2015 8 pasang (16)

6.29± 3.52
years
zali 2015 12 12 12 (pre post)

4 to 12 years

kang
jenis stem cell dosis outcome GMFM pre/kontrol
UCT-MSC Single-dose (2 × 107) cells GMFM66, (MAS), (PEDI),(CP- 1m: −0.02 [−4.79, 4.75]
QoL), mean changes in (FA) and 3m: 2.03 [−2.97, 7.04]
MD of CST, PTR 6m: −0.58 [−5.32, 4.15]
12m:1.23 [−3.33, 5.80]

autologous M2 0.8 ± 0.12 × 106/kg Gross Motor Function Measure 13.7 ± 7.8
macrophages 66 (66-item GMFM) test,
Peabody Developmental Motor
Scale-Fine Motor (PDMS-FM)
test, Ashworth scale, MRC scale

Human Wharton’s one- or two-course (four or GMFM 88, FMFM grup A 119 37 ± 90 18
Jelly eight times lumbar puncture, 4
or 8 × 107 hWJSCs

human umbilical cord (4.5~5.5 × 107) ADL< GFGM 88,F-FDG/PET CT 1m: 4.053 ± 3.001
mesenchymal stem 3m: 15.700 ± 6.746
cells (hUC- MSCs) 6m: 28.900 ± 8.807
12m:36.800 ± 8.802

human umbilical cord 4x 5.107 GMFM 88, CFA< MRI, EEG 3m: 1.74± 0.39 6m: 2.96±0.32;
blood mesenchymal 12m : 4.75±0.28; 24m:
stem cell (hUCB- 4.81±0.39
MSC)

250 IU/kg of rhEPO, gmfm 88, BSID-II

subcutaneously twice a week
until Hb 15, mean injek: 7.2x

21.71±10.06
Bone marrow 4x 1 × 106/kg body weight GMFM; FMFM baseline : 95.26 ± 29.19; 3m :
mesenchymal stem interval 3-4days 97.34 ± 28.96; 6m: 99.86 ±
cells (BMMSCs) and 28.48*; 12m: 102.51 ± 28.30
bone marrow
mononuclear cells
(BMMNCs)
GMFM; PDMS-FM baseline :
1.35 ± 1.28; 1year:3.92 ± 2.33
aborted human fetal
forebrain tissue
neuron progenitor 8–10 × 106 of neural progenitor
cell cells in 200 μl normal saline
 1st inj: mononuclear cell dan GMFM88 ; GMFM 66; MAS GMFM 88 : baseline : 16.7
CD34+:27.2 × 106 and 2.6 × 106; [12.3; 21.1]; GMFM 66
2nd inj : 17.1 × 106 and 1.7 × baseline 24.8 [21.4; 28.1]
bone Marrow 106.
Mononuclear Cells
(BMMNCs)
GMFM 66; PMDMS 2; MRI mean change : 6.9 points (SD
5.5)

1–5x10*7 total nucleated cells per

autologous cord blood kilogram of ACB
GMFM88, GMFM 66 persentil; GMFM 88 baseline : IQR 18.3
MAS (17.6); GMFM 66 %%
injeksi pertama mononuclear 19.3(19.6)
cells and CD34+ cells per kg
bone marrow body weight were 17.4 ± 11.9 ×
mononuclear cell 106 and 1.5 ± 1.4 × 106;; injeksi
(BMMC) kedua 15.0 ± 12.8 × 106 and 1.1 ± 1.1 × 106,
1 course (4x1.0-1.5 x10^7)

umbilical cordederived
mesenchymal stromal
cell (UCMSC)
autologous bone GMFM 66; GMFCs, FIM, FAM,
marrowederived BBS, MAS
CD133þ cell
intrathecal

13.6 ± 10.6

GMFM basline :29.29 (5.85); kontrol

basline : 29.40 (6.89)
 kombinasi
GMFM post/exp follow up periode Kolom1 Kolom2 fisiotx
1m: 4.47 [−0.73, 9.68] 12m 1m (β 4.59, 95%CI -1.16 to 10.35,
3m: 6.85 [1.49, 12.20]; Cohen’s d 0.45)] ; 3m (β 4.81,
6m: 11.27 [6.01, 16.53] 95%CI −0.23, 9.86, Cohen’s d 0.48)
12m : 10.65 [5.39, 15.91] 6m: (β 11.90, 95%CI 5.42, 18.37,
Cohen’s d 1.11)
12m (β 8.07, 95%CI 1.62 to 14.52,
58.6±14.6 3m Cohen’s d 0.92) fisiotx dilanjut
setelah stem
sel terapi
selesai

grup A123 20 ± 89 01 6m(1 course)' 12m : which was significantly higher yg grup B no
(1&2course) than the pretreatment com- posite tabel2 gitu interference
score (p < 0 001) due to other
related
treatments,
such as
rehabilitation,
1m:− 1.316 ± 3.429 1m,3m, 6m,12m 1m p=0.237; 3m p=0.062 exclude :
traditional
3m:32.053 ± 5.028; 6m:p=0.037* participation
Chinese in
6m :59.000 ± 8.947 12m :p=0.045* medicine,
other clinicalor
12m : 64.526 ± 9.600 surgery,
trials within
within 3
the three
months prior to
months prior
screening,
to enrollment
3m: 4.59 ± 0.26; 6m: 3,6,12,24 noand NAduring
7.62±0.47; 12m : treatment.
interferences
10.27±0.57; 24m: due to other
12.66±0.66 related
treatments
within 3
tabel gitu months NAprior
to the
enrolment and
during the
treatment,
40.03±14.79 such as
BMMSC= baseline : 95.21 3,6,12 m rehabilita-
± 32.69; 3m: 113.15 ± tion,treatment
The
34.93; 6m : 122 ± 35.50' traditional
group received
12m :127.03 ± 35.80------ Chinese
BMMNC = baseline: cell
95.68 ± 30.79; 3m: 99.47 ± medicine, and
transplantatio
30.89*; 6m: 104.76 ± surgery
n and
baseline : 1.42
31.39; 12m ± 1.30;
: 111.91 ± 1y rehabilitation
1year:31.68
5.69 ± 2.91 training, and
the controls
only received
rehabilitation
training.
 received ex-
tensive
rehabilitative
therapy by
rehabilitative
GMFM 88 6m : 41.8 [34.8; 3m(1x injeksi), 6m(2x inj) NA and
physicians
48.7]*; GMFM 66 : 6m: physiotherapis
40.0 [36.3; 43.6]*
ts for 12 days
(1 h per day)
at the re-
habilitative
mean change : 7.5 points 1y centerNAof
(SD 6.8) Vinmec Times
City
International
Hospital.
Parents were
6m GMFM 88 : IQR 35.8 6m, 12m instructed on
(27.6); GMFM 66 %%22.5 how to
(22.6);; 12m: GMFM 88: perform
IQR 53.2 (28.2); GMFM continuous
66% 40.1 (5.5)
rehabilitative
at home.

6m P = 0.015 NA

19.7 ± 14.0;

change : 7.08 (2.04);

changed kontrol :3.85
(0.91)
penilaian gm studi design
nilai
perubahan nya

skor gmfm asli

skor gmfm asli rct

nilai
perubahan nya

skor gmfm asli

uncontrolled clinical trial t

skor gmfm asli

randomised,
skor gmfm asli rct
skor gmfm asli

An open label
uncontrolled
clinical trial
nilai
perubahan nya

skor gmfm asli

An open-label,
uncontrolled
clinical tria

skor gmfm asli

nilai
perubahan nya